Want to join the conversation?
$ORCL FY15 10-K: At May 31, 2015 (vs. at May 31, 2014): As per Oracle’s transfer agent, it had 11,383 stockholders of record. ORCL had $42Bil of senior notes outstanding vs. $24.1Bil. R&D expense was $5.5Bil in FY15 vs. $5.2Bil in FY14. Oracle issued $20Bil of senior notes during FY15 in comparison to EUR2Bil and $3Bil of senior notes during FY14.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.